CTMX Q1 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+159.9% YoY

Gross Profit

$22M93.6% margin

Operating Income

-$6M-24.1% margin

Net Income

-$3M-14.1% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+16.8%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$235M

Total Liabilities

$321M

Stockholders' Equity

-$87M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$9M	+159.9%
Gross Profit	$22M	$9M	+143.4%
Operating Income	-$6M	-$32M	+82.4%
Net Income	-$3M	-$32M	+89.6%